The role of Huaiqihuang Granules in the long-term management of bronchial asthma in young children: a multicenter real-world study
10.3760/cma.j.cn101070-20230208-00103
- VernacularTitle:槐杞黄颗粒在年幼儿童支气管哮喘长期管理中作用的多中心真实世界研究
- Author:
Huimin WANG
1
;
Jinghui MU
;
Chuanhe LIU
;
Changshan LIU
;
Ying WANG
;
Zhiying HAN
;
Xin SUN
;
Xing CHEN
;
Shuhua AN
;
Dolikon MUZAPAR
;
Aiping LU
;
Min WANG
;
Yan CHENG
;
Xiaomei YIN
;
Hanmin LIU
;
Hong WANG
;
Shan HUA
;
Li DONG
;
Ying HUANG
;
Yi JIANG
;
Jianxin XIONG
;
Shenggang DING
;
Wei WANG
;
Shunying ZHAO
;
Yuzhi CHEN
Author Information
1. 首都儿科研究所附属儿童医院变态反应科，北京 100020
- Keywords:
Child;
Bronchial asthma;
Treatment;
Huaiqihuang granules
- From:
Chinese Journal of Applied Clinical Pediatrics
2023;38(4):286-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the role of Huaiqihuang Granules (HQ) in the long-term management of bronchial asthma in young children, and the effective effect on concomitant rhinitis.Methods:A prospective real-world multicenter study was conducted in children aged 2-5 years with asthma diagnosed in the outpatient department (from April 2016 to March 2019)who received either inhaled corticosteroid (ICS)/leukotriene receptor antagonist (LTRA)(control group); inhaled ICS/LTRA plus HQ(combination group), or HQ alone(HQ group). All patients were followed up at week 4, 8, 12 after treatment. The number of days with asthma symptoms, the frequency of severe asthma attacks, the level of asthma control, and the days with rhinitis symptoms in the last 4 weeks were recorded. Differences before and after treatment, and those among groups after treatment were compared using Kruskal- Wallis H test or Wilcoxon rank-sum test. Results:A total of 2 234 eligible patients were recruited, and 2 147 cases completed followed-up visits, including 477, 1 374 and 296 cases in the control group, combination group, and HQ group, respectively. After the treatment, all 3 groups showed significant declines in the days with asthma symptoms, frequency of severe asthma attack and the days with rhinitis symptoms (all P<0.01), and the rate of well-controlled asthma increased significantly ( P<0.01). It lasted until the end of follow-up. Among groups, patients in the combination group showed significantly less days of asthma symptoms than those of the other 2 group at week 8 and 12[0(0, 0.9) d vs.0(0, 0.3) d, P<0.05; 0(0, 0.1) d vs. 0(0, 1.0) d, P<0.01]. Patients in the combination group and HQ group showed a significantly lower rate of severe asthma attacks than that of the control group at week 12 [0(0, 1), 0(0, 1), 0(0, 2), all P<0.05]. The well-controlled rate of asthma in the combination group was significantly higher than that of the control group and HQ group at week 8 and 12 (89.6% vs. 85.9% vs.82.1%, H=15.28; 90.9% vs. 84.1% vs. 81.8%, χ2=29.32, all P<0.01). Conclusions:HQ can significantly alleviate symptoms of asthma and rhinitis, severe attack of asthma, and increase the control rate of asthma when used as an additional treatment or used alone.
